5-HT1A receptor-dependent control of nigrostriatal dopamine neurotransmission in the pharmacotherapy of Parkinson's disease and schizophrenia

Behavioural Pharmacology

Volumn 26, Issue , 2015, Pages 45-58

  Haleem, Darakhshan J ^a  

^a UNIVERSITY OF KARACHI   (Pakistan)

Author keywords

5 hydroxytryptamine 1A receptor; basal ganglia; dopamine; nigrostriatal pathway; Parkinson's disease; schizophrenia

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; CHLORPROMAZINE; CLOZAPINE; DOPAMINE; DOPAMINE 2 RECEPTOR; HALOPERIDOL; LEVODOPA; PERGOLIDE; ROPINIROLE; SEROTONIN; SEROTONIN 1A AGONIST; SEROTONIN 1A RECEPTOR; TALIPEXOLE; ANTIPARKINSON AGENT; NEUROLEPTIC AGENT;

ARTICLE; ATTENUATION; BASAL GANGLION; CATALEPSY; CORPUS STRIATUM; DOPAMINERGIC TRANSMISSION; DRUG EFFECT; DRUG MECHANISM; FEEDBACK SYSTEM; HUMAN; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PRESYNAPTIC NERVE; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; SYNAPSE; SYNTHESIS; ANIMAL; DORSAL RAPHE NUCLEUS; DRUG DESIGN; DRUG EFFECTS; METABOLISM; PATHOLOGY;

ANIMALS; ANTIPARKINSON AGENTS; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA; CORPUS STRIATUM; DOPAMINE; DORSAL RAPHE NUCLEUS; DRUG DESIGN; HUMANS; PARKINSON DISEASE; RECEPTOR, SEROTONIN, 5-HT1A; RECEPTORS, DOPAMINE D2; SCHIZOPHRENIA;

EID: 84925485362     PISSN: 09558810     EISSN: 14735849     Source Type: Journal    
DOI: 10.1097/FBP.0000000000000123     Document Type: Article

References (196)

1. Abbott A (2010). Levodopa: the story so far. Nature 466:S6-S7.
2. Ahlskog JE, Muenter MD (2001). Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 16:448-458.
3. Albin RL, Young AB, Penney JB (1989). The functional anatomy of basal ganglia disorders. Trends Neurosci 12:366-375.
4. Alex KD, Pehek EA (2007). Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission. Pharmacol Ther 113:296-320.
5. Antonelli T, Fuxe K, Tomasini MC, Bartoszyk GD, Seyfried CA, Tanganelli S, Ferraro L (2005). Effects of sarizotan on the corticostriatal glutamate pathways. Synapse 58:193-199.
6. Antonini A, Siri C, Santangelo G, Cilia R, Poletti M, Canesi M, et al. (2011). Mov Disord 26:464-468.
7. Arborelius L, Chergui K, Murase S, Nomikos GG, Höök BB, Chouvet G, et al. (1993). The 5-HT1A receptor selective ligands, (R)-8-OH-DPAT and (S)-UH-301, differentially affect the activity of midbrain dopamine neurons. Naunyn Schmiedebergs Arch Pharmacol 347:353-362.
8. Arvidsson LE, Hacksell U, Nilsson JL, Hjorth S, Carlsson A, Lindberg P, et al. (1981). 8-Hydroxy-2-(di-n-propylamino)tetralin, a new centrally acting 5-hydroxytryptamine receptor agonist. J Med Chem 24:921-923.
9. Arvidsson LE, Johansson AM, Hacksell U, Nilsson JL, Svensson K, Hjorth S, et al. (1987). (+)-Cis-8-hydroxy-1-methyl-2-(di-n-propylamino)tetralin: a potent and highly stereoselective 5-hydroxytryptamine receptor agonist. J Med Chem 30:2105-2109.
10. Assié MB, KoekW (2000). [(3)H]-8-OH-DPAT binding in the rat brain raphe area: involvement of 5-HT(1A) and non-5-HT(1A) receptors. Br J Pharmacol 130: 1348-1352.
11. Assié MB, Ravailhe V, Faucillon V, Newman-Tancredi A (2005). Contrasting contribution of 5-hydroxytryptamine 1A receptor activation to neurochemical profile of novel antipsychotics: frontocortical dopamine and hippocampal serotonin release in rat brain. J Pharmacol Exp Ther 315:265-272.
12. Azmitia EC, Buchan AM, Williams JH (1978). Structural and functional restoration by collateral sprouting of hippocampal 5-HT axons. Nature 274:374-376.
13. Baik JH (2013). Dopamine signaling in reward-related behaviors. Front Neural Circuits 7:152.
14. Banasr M, Hery M, Printemps R, Daszuta A (2004). Serotonin-induced increases in adult cell proliferation and neurogenesis are mediated through different and common 5-HT receptor subtypes in the dentate gyrus and the subventricular zone. Neuropsychopharmacology 29:450-460.
15. Bantick RA, Deakin JF, Grasby PM (2001). The 5-HT1A receptor in schizophrenia: a promising target for novel atypical neuroleptics? J Psychopharmacol 15: 37-46.
16. Bantick RA, Montgomery AJ, Bench CJ, Choudhry T, Malek N, McKenna PJ, et al. (2004). A positron emission tomography study of the 5-HT1A receptor in schizophrenia and during clozapine treatment. J Psychopharmacol 18: 346-354.
17. Beart PM, McDonald D (1982). 5-Hydroxytryptamine and 5-hydroxytryptaminergic-dopaminergic interactions in the ventral tegmental area of rat brain. J Pharm Pharmacol 34:591-593.
18. Bergquist F, Shahabi HN, Nissbrandt H (2003). Somatodendritic dopamine release in rat substantia nigra influences motor performance on the accelerating rod. Brain Res 973:81-91.
19. Blier P, Ward NM (2003). Is there a role for 5-HT1A agonists in the treatment of depression? Biol Psychiatry 53:193-203.
20. Bockaert J, Dumuis A, Bouhelal R, Sebben M, Cory RN (1987). Piperazine derivatives including the putative anxiolytic drugs, buspirone and ipsapirone, are agonists at 5-HT1A receptors negatively coupled with adenylate cyclase in hippocampal neurons. Naunyn Schmiedebergs Arch Pharmacol 335:588-592.
21. Bonaventure P, Nepomuceno D, Kwok A, Chai W, Langlois X, Hen R, et al. (2002). Reconsideration of 5-hydroxytryptamine (5-HT)(7) receptor distribution using [(3)H]5-carboxamidotryptamine and [(3)H]8-hydroxy-2-(di-n-propylamino) tetraline: analysis in brain of 5-HT(1A) knockout and 5-HT(1A/1B) double-knockout mice. J Pharmacol Exp Ther 302:240-248.
22. Bonvento G, Scatton B, Claustre Y, Rouquier L (1992). Effect of local injection of 8-OH-DPAT into the dorsal or median raphe nuclei on extracellular levels of serotonin in serotonergic projection areas in the rat brain. Neurosci Lett 137:101-104.
23. Braak H, Del Tredici K, Rüb U, de Vos RA, Jansen Steur EN, Braak E (2003). Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24:197-211.
24. Bubar MJ, Cunningham KA (2006). Serotonin 5-HT2A and 5-HT2C receptors as potential targets for modulation of psychostimulant use and dependence. Curr Top Med Chem 6:1971-1985.
25. Calabresi P, Di Filippo M, Ghiglieri V, Picconi B (2008). Molecular mechanisms underlying levodopa-induced dyskinesia. Mov Disord 23 Suppl 3: S570-S579.
26. Carlsson A (1988). The current status of the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1:179-186.
27. Carron R, Fraix V, Maineri C, Seigneuret E, Piallat B, Krack P, et al. (2011). High frequency deep brain stimulation of the subthalamic nucleus versus continuous subcutaneous apomorphine infusion therapy: a review. J Neural Transm 118:915-924.
28. Cenci MA, Ohlin KE, Odin P (2011). Current options and future possibilities for the treatment of dyskinesia and motor fluctuations in Parkinson's disease. CNS Neurol Disord Drug Targets 10:670-684.
29. Chen CP, Alder JT, Bray L, Kingsbury AE, Francis PT, Foster OJ (1998). Postsynaptic 5-HT1A and 5-HT2A receptors are increased in Parkinson's disease neocortex. Ann N Y Acad Sci 861:288-289.
30. Clark MS, McDevitt RA, Neumaier JF (2006). Quantitative mapping of tryptophan hydroxylase-2, 5-HT1A, 5-HT1B, and serotonin transporter expression across the anteroposterior axis of the rat dorsal and median raphe nuclei. J Comp Neurol 498:611-623.
31. Cole JC, Rodgers RJ (1994). Ethological evaluation of the effects of acute and chronic buspirone treatment in the murine elevated plus-maze test: comparison with haloperidol. Psychopharmacology (Berl) 114:288-296.
32. Dahlström A, Fuxe K (1964). Localization of monoamines in the lower brain stem. Experientia 20:398-399.
33. Davies J, Tongroach P (1978). Neuropharmacological studies on the nigro-striatal and raphe-striatal system in the rat. Eur J Pharmacol 51:91-100.
34. Davis JM, Chen N, Glick ID (2003). A meta-analysis of the efficacy of secondgeneration antipsychotics. Arch Gen Psychiatry 60:553-564.
35. Davis MC, Horan WP, Marder SR (2014). Psychopharmacology of the negative symptoms: current status and prospects for progress. Eur Neuropsychopharmacol 24:788-799.
36. DeLeon A, Patel NC, Crismon ML (2004). Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability. Clin Ther 26:649-666.
37. DeLong MR (1990). Primate models of movement disorders of basal ganglia origin. Trends Neurosci 13:281-285.
38. Di Giovanni G, Di Matteo V, Pierucci M, Esposito E (2008). Serotonin-dopamine interaction: electrophysiological evidence. Prog Brain Res 172:45-71.
39. Di Matteo V, Di Giovanni G, Pierucci M, Esposito E (2008). Serotonin control of central dopaminergic function: focus on in vivo microdialysis studies. Prog Brain Res 172:7-44.
40. Doherty MD, Pickel VM (2001). Targeting of serotonin 1A receptors to dopaminergic neurons within the parabrachial subdivision of the ventral tegmental area in rat brain. J Comp Neurol 433:390-400.
41. Dray A, Davies J, Oakley NR, Tongroach P, Vellucci S (1978). The dorsal and medial raphe projections to the substantia nigra in the rat: electrophysiological, biochemical and behavioural observations. Brain Res 151: 431-442.
42. Dremencov E, Weizmann Y, Kinor N, Gispan-Herman I, Yadid G (2006). Modulation of dopamine transmission by 5HT2C and 5HT3 receptors: a role in the antidepressant response. Curr Drug Targets 7:165-175.
43. Dupre KB, Eskow KL, Steiniger A, Klioueva A, Negron GE, Lormand L, et al. (2008). Effects of coincident 5-HT1A receptor stimulation and NMDA receptor antagonism on L-DOPA-induced dyskinesia and rotational behaviors in the hemi-parkinsonian rat. Psychopharmacology (Berl) 199:99-108.
44. Eskow KL, Dupre KB, Barnum CJ, Dickinson SO, Park JY, Bishop C (2009). The role of the dorsal raphe nucleus in the development, expression, and treatment of L-dopa-induced dyskinesia in hemiparkinsonian rats. Synapse 63:610-620.
45. Esposito E (2006). Serotonin-dopamine interaction as a focus of novel antidepressant drugs. Curr Drug Targets 7:177-185.
46. Evans AK, Reinders N, Ashford KA, Christie IN, Wakerley JB, Lowry CA (2008). Evidence for serotonin synthesis-dependent regulation of in vitro neuronal firing rates in the midbrain raphe complex. Eur J Pharmacol 590:136-149.
47. Fahn S, Libsch LR, Cutler RW (1971). Monoamines in the human neostriatum: topographic distribution in normals and in Parkinson's disease and their role in akinesia, rigidity, chorea, and tremor. J Neurol Sci 14:427-455.
48. Farde L, Nordström AL, Wiesel FA, Pauli S, Halldin C, Sedvall G (1992). Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry 49:538-544.
49. Feyder M, Bonito-Oliva A, Fisone G (2011). L-DOPA-induced dyskinesia and abnormal signaling in striatal medium spiny neurons: focus on dopamine D1 receptor-mediated transmission. Front Behav Neurosci 5:71.
50. Fink KB, Göthert M (2007). 5-HT receptor regulation of neurotransmitter release. Pharmacol Rev 59:360-417.
51. Fox SH, Chuang R, Brotchie JM (2009). Serotonin and Parkinson's disease: on movement, mood, and madness. Mov Disord 24:1255-1266.
52. Frankle WG, Lombardo I, Kegeles LS, Slifstein M, Martin JH, Huang Y, et al. (2006). Serotonin 1A receptor availability in patients with schizophrenia and schizo-affective disorder: a positron emission tomography imaging study with [11C]WAY 100635. Psychopharmacology (Berl) 189:155-164.
53. Gerber R, Altar CA, Liebman JM (1988). Rotational behavior induced by 8-hydroxy-DPAT, a putative 5HT-1A agonist, in 6-hydroxydopamine-lesioned rats. Psychopharmacology (Berl) 94:178-182.
54. Gerfen CR, Surmeier DJ (2011). Modulation of striatal projection systems by dopamine. Annu Rev Neurosci 34:441-466.
55. Geyer MA (1996). Serotonergic functions in arousal and motor activity. Behav Brain Res 73:31-35.
56. Glaser T, Traber J (1983). Buspirone: action on serotonin receptors in calf hippocampus. Eur J Pharmacol 88:137-138.
57. Gobert A, Rivet JM, Cistarelli L, Melon C, Millan MJ (1999). Buspirone modulates basal and fluoxetine-stimulated dialysate levels of dopamine, noradrenaline and serotonin in the frontal cortex of freely moving rats: activation of serotonin1A receptors and blockade of alpha2-adrenergic receptors underlie its actions. Neuroscience 93:1251-1262.
58. Goff DC, Midha KK, Brotman AW, McCormick S,Waites M, Amico ET (1991). An open trial of buspirone added to neuroleptics in schizophrenic patients. J Clin Psychopharmacol 11:193-197.
59. Gozlan H, El Mestikawy S, Pichat L, Glowinski J, Hamon M (1983). Identification of presynaptic serotonin autoreceptors using a new ligand: 3H-PAT. Nature 305:140-142.
60. Green B (2004). Focus on aripiprazole. Curr Med Res Opin 20:207-213.
61. Groenewegen HJ (2003). The basal ganglia and motor control. Neural Plast 10:107-120.
62. Gross G,Wicke K, Drescher KU (2013). Dopamine D3 receptor antagonism-still a therapeutic option for the treatment of schizophrenia. Naunyn Schmiedebergs Arch Pharmacol 386:155-166.
63. Haider S, Khaliq S, Ahmed SP, Haleem DJ (2006). Long-term tryptophan administration enhances cognitive performance and increases 5HT metabolism in the hippocampus of female rats. Amino Acids 31:421-425.
64. Haider S, Khaliq S, Tabassum S, Haleem DJ (2012). Role of somatodendritic and postsynaptic 5-HT1A receptors on learning and memory functions in rats. Neurochem Res 37:2161-2166.
65. Hajós M, Hoffmann WE, Tetko IV, Hyland B, Sharp T, Villa AE (2001). Different tonic regulation of neuronal activity in the rat dorsal raphe and medial prefrontal cortex via 5-HT(1A) receptors. Neurosci Lett 304:129-132.
66. Haleem DJ (2006). Serotonergic modulation of dopamine neurotransmission: a mechanism for enhancing therapeutics in schizophrenia. J Coll Physicians Surg Pak 16:556-562.
67. Haleem DJ (2011a). Behavioral deficits and exaggerated feedback control over raphe-hippocampal serotonin neurotransmission in restrained rats. Pharmacol Rep 63:888-897.
68. Haleem DJ (2011b). Raphe-hippocampal serotonin neurotransmission in the sex related differences of adaptation to stress: focus on serotonin-1A receptor. Curr Neuropharmacol 9:512-521.
69. Haleem DJ (2013). Extending therapeutic use of psychostimulants: focus on serotonin-1A receptor. Prog Neuropsychopharmacol Biol Psychiatry 46:170-180.
70. Haleem DJ, Khan NH (2003). Enhancement of serotonin-1A receptor dependent responses following withdrawal of haloperidol in rats. Prog Neuropsychopharmacol Biol Psychiatry 27:645-651.
71. Haleem DJ, Batool F, Khan NH, Kamil N, Ali O, Saify ZS, Haleem MA (2002). Differences in the effects of haloperidol and clozapine on brain serotonin and dopamine metabolism and on tests related to extrapyramidal functions in rats. Med Sci Monit 8:BR354-BR361.
72. Haleem DJ, Shireen E, Haleem MA (2004). Somatodendritic and postsynaptic serotonin-1A receptors in the attenuation of haloperidol-induced catalepsy. Prog Neuropsychopharmacol Biol Psychiatry 28:1323-1329.
73. Haleem DJ, Samad N, Haleem MA (2007a). Reversal of haloperidol-induced extrapyramidal symptoms by buspirone: a time-related study. Behav Pharmacol 18:147-153.
74. Haleem DJ, Samad N, Haleem MA (2007b). Reversal of haloperidol-induced tardive vacuous chewing movements and supersensitive somatodendritic serotonergic response by buspirone in rats. Pharmacol Biochem Behav 87:115-121.
75. Haleem DJ, Ikram H, Haleem MA (2014). Inhibition of apomorphine-induced conditioned place preference in rats co-injected with buspirone: relationship with serotonin and dopamine in the striatum. Brain Res 1586:73-82.
76. Hall H, Lundkvist C, Halldin C, Farde L, Pike VW, McCarron JA, et al. (1997). Autoradiographic localization of 5-HT1A receptors in the post-mortem human brain using [3H]WAY-100635 and [11C]way-100635. Brain Res 745: 96-108.
77. Halliday GM, Blumbergs PC, Cotton RG, Blessing WW, Geffen LB (1990). Loss of brainstem serotonin-and substance P-containing neurons in Parkinson's disease. Brain Res 510:104-107.
78. Hensler JG, Artigas F, Bortolozzi A, Daws LC, De Deurwaerdère P, Milan L, et al. (2013). Catecholamine/serotonin interactions: systems thinking for brain function and disease. Adv Pharmacol 68:167-197.
79. Herold C, Palomero-Gallagher N, Güntürkün O, Zilles K (2012). Serotonin 5-HT (1A) receptor binding sites in the brain of the pigeon (Columba livia). Neuroscience 200:1-12.
80. Hervás I, Bel N, Fernández AG, Palacios JM, Artigas F (1998). In vivo control of 5-hydroxytryptamine release by terminal autoreceptors in rat brain areas differentially innervated by the dorsal and median raphe nuclei. Naunyn Schmiedebergs Arch Pharmacol 358:315-322.
81. Hervé D, Pickel VM, Joh TH, Beaudet A (1987). Serotonin axon terminals in the ventral tegmental area of the rat: fine structure and synaptic input to dopaminergic neurons. Brain Res 435:71-83.
82. Hillegaart V (1990). Effects of local application of 5-HT and 8-OH-DPAT into the dorsal and median raphe nuclei on motor activity in the rat. Physiol Behav 48:143-148.
83. Honigfeld G, Arellano F, Sethi J, Bianchini A, Schein J (1998). Reducing clozapine-related morbidity and mortality: 5 years of experience with the Clozaril National Registry. J Clin Psychiatry 59 Suppl 3:3-7.
84. Hornykiewicz O, Kish SJ (1987). Biochemical pathophysiology of Parkinson's disease. Adv Neurol 45:19-34.
85. Hoyer D, Hannon JP, Martin GR (2002). Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol Biochem Behav 71:533-554.
86. Hui YP, Zhang QJ, Zhang L, Chen L, Guo Y, Qiao HF, et al. (2014). Activation of prelimbic 5-HT1A receptors produces antidepressant-like effects in a unilateral rat model of Parkinson's disease. Neuroscience 268:265-275.
87. Huot P, Fox SH (2013). The serotonergic system in motor and non-motor manifestations of Parkinson's disease. Exp Brain Res 230:463-476.
88. Huot P, Fox SH, Brotchie JM (2011). The serotonergic system in Parkinson's disease. Prog Neurobiol 95:163-212.
89. Huot P, Johnston TH, Visanji NP, Darr T, Pires D, Hazrati LN, et al. (2012). Increased levels of 5-HT1A receptor binding in ventral visual pathways in Parkinson's disease. Mov Disord 27:735-742.
90. Ichikawa J, Meltzer HY (2000). The effect of serotonin(1A) receptor agonism on antipsychotic drug-induced dopamine release in rat striatum and nucleus accumbens. Brain Res 858:252-263.
91. Ichikawa J, Ishii H, Bonaccorso S, Fowler WL, O'Laughlin IA, Meltzer HY (2001). 5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT (1A) receptor activation: a possible mechanism of atypical antipsychoticinduced cortical dopamine release. J Neurochem 76:1521-1531.
92. Ikram H, Haleem DJ (2011). Attenuation of apomorphine-induced sensitization by buspirone. Pharmacol Biochem Behav 99:444-450.
93. Ishibashi T, Horisawa T, Tokuda K, Ishiyama T, Ogasa M, Tagashira R, et al. (2010). Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity. J Pharmacol Exp Ther 334:171-181.
94. Jankovic J (2008). Parkinson's disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry 79:368-376.
95. Jankovic J, Aguilar LG (2008). Current approaches to the treatment of Parkinson's disease. Neuropsychiatr Dis Treat 4:743-757.
96. Javid FA, Naylor RJ (2006). The effect of the 5-HT1A receptor agonist, 8-OHDPAT, on motion-induced emesis in Suncus murinus. Pharmacol Biochem Behav 85:820-826.
97. Jordan S, Koprivica V, Chen R, Tottori K, Kikuchi T, Altar CA (2002). The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol 441:137-140.
98. Kane JM (1999). Management strategies for the treatment of schizophrenia. J Clin Psychiatry 60 Suppl 12:13-17.
99. Kane J, Honigfeld G, Singer J, Meltzer H (1988). Clozapine for the treatmentresistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45:789-796.
100. Kelland MD, Freeman AS, Chiodo LA (1990). Serotonergic afferent regulation of the basic physiology and pharmacological responsiveness of nigrostriatal dopamine neurons. J Pharmacol Exp Ther 253:803-811.
101. Kikuchi T, Tottori K, Uwahodo Y, Hirose T, Miwa T, Oshiro Y, Morita S (1995). 7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity. J Pharmacol Exp Ther 274:329-336.
102. Kim SW, Shin IS, Kim JM, Lee JH, Lee YH, Yang SJ, Yoon JS (2009). Effectiveness of switching to aripiprazole from atypical antipsychotics in patients with schizophrenia. Clin Neuropharmacol 32:243-249.
103. Kiss B, Horváth A, Némethy Z, Schmidt E, Laszlovszky I, Bugovics G, et al. (2010). Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile. J Pharmacol Exp Ther 333:328-340.
104. Knobelman DA, Kung HF, Lucki I (2000). Regulation of extracellular concentrations of 5-hydroxytryptamine (5-HT) in mouse striatum by 5-HT(1A) and 5-HT (1B) receptors. J Pharmacol Exp Ther 292:1111-1117.
105. Köhler C, Steinbusch H (1982). Identification of serotonin and non-serotonincontaining neurons of the mid-brain raphe projecting to the entorhinal area and the hippocampal formation. A combined immunohistochemical and fluorescent retrograde tracing study in the rat brain. Neuroscience 7:951-975.
106. Kotagale NR, Taksande BG, Wadhwani PJ, Palhade MW, Mendhi SM, Gawande DY, et al. (2012). Psychopharmacological study of agmatine in behavioral tests of schizophrenia in rodents. Pharmacol Biochem Behav 100:398-403.
107. Kravitz AV, Freeze BS, Parker PR, Kay K, Thwin MT, Deisseroth K, Kreitzer AC (2010). Regulation of parkinsonian motor behaviours by optogenetic control of basal ganglia circuitry. Nature 466:622-626.
108. Kuipers W, Kruse CG, van Wijngaarden I, Standaar PJ, Tulp MT, Veldman N, et al. (1997). 5-HT1A-versus D2-receptor selectivity of flesinoxan and analogous N4-substituted N1-arylpiperazines. J Med Chem 40:300-312.
109. Laporte AM, Lima L, Gozlan H, Hamon M (1994). Selective in vivo labelling of brain 5-HT1A receptors by [3H]WAY 100635 in the mouse. Eur J Pharmacol 271:505-514.
110. Lerond J, Lothe A, Ryvlin P, Bouvard S, d'Amato T, Ciumas C, et al. (2013). Effects of aripiprazole, risperidone, and olanzapine on 5-HT1A receptors in patients with schizophrenia. J Clin Psychopharmacol 33:84-89.
111. Leucht S, Wahlbeck K, Hamann J, Kissling W (2003). New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 361:1581-1589.
112. Lieberman JA (2004). Dopamine partial agonists: a new class of antipsychotic. CNS Drugs 18:251-267.
113. Liebman JM, Gerber R, Hall NR, Altar CA (1988). Heterogeneous rotational responsiveness in 6-hydroxydopamine-denervated rats: pharmacological and neurochemical characterization. Psychopharmacology (Berl) 96:477-483.
114. Lucas JJ, Segu L, Hen R (1997). 5-Hydroxytryptamine1B receptors modulate the effect of cocaine on c-fos expression: converging evidence using 5-hydroxytryptamine1B knockout mice and the 5-hydroxytryptamine1B/1D antagonist GR127935. Mol Pharmacol 51:755-763.
115. Mahmood D, Khanam R, Pillai KK, Akhtar M (2012). Protective effects of histamine H3-receptor ligands in schizophrenic behaviors in experimental models. Pharmacol Rep 64:191-204.
116. Marco EJ, Moreno MJ, de Pablo AL (1999). Local treatments of dorsal raphe nucleus induce changes in serotonergic activity in rat major cerebral arteries. Stroke 30:1695-1701.
117. Marston HM, Young JW, Martin FD, Serpa KA, Moore CL,Wong EH, et al. (2009). Asenapine effects in animal models of psychosis and cognitive function. Psychopharmacology (Berl) 206:699-714.
118. Masana M, Santana N, Artigas F, Bortolozzi A (2012). Dopamine neurotransmission and atypical antipsychotics in prefrontal cortex: a critical review. Curr Top Med Chem 12:2357-2374.
119. Mason SL, Reynolds GP (1992). Clozapine has sub-micromolar affinity for 5-HT1A receptors in human brain tissue. Eur J Pharmacol 221:397-398.
120. Matsuda T, Yoshikawa T, Suzuki M, Asano S, Somboonthum P, Takuma K, et al. (1995). Novel benzodioxan derivative, 5-(3-[((2S)-1,4-benzodioxan-2-ylmethyl) amino]propoxy)-1,3-benzodioxole HCl (MKC-242), with a highly potent and selective agonist activity at rat central serotonin1A receptors. Jpn J Pharmacol 69:357-366.
121. Matthews PR, Harrison PJ (2012). A morphometric, immunohistochemical, and in situ hybridization study of the dorsal raphe nucleus in major depression, bipolar disorder, schizophrenia, and suicide. J Affect Disord 137:125-134.
122. McCreary AC, Jones CA (2010). Antipsychotic medication: the potential role of 5-HT(1A) receptor agonism. Curr Pharm Des 16:516-521.
123. Mehler-Wex C, Riederer P, Gerlach M (2006). Dopaminergic dysbalance in distinct basal ganglia neurocircuits: implications for the pathophysiology of Parkinson's disease, schizophrenia and attention deficit hyperactivity disorder. Neurotoxicity Research 10:1-12.
124. Meltzer HY (1991). The mechanism of action of novel antipsychotic drugs. Schizophr Bull 17:263-287.
125. Meltzer HY (1995). Clozapine: is another view valid? Am J Psychiatry 152:821-825.
126. Meltzer HY (2012). Clozapine: balancing safety with superior antipsychotic efficacy. Clin Schizophr Relat Psychoses 6:134-44.
127. Meltzer HY, Sumiyoshi T (2008). Does stimulation of 5-HT(1A) receptors improve cognition in schizophrenia? Behav Brain Res 195:98-102.
128. Meltzer HY, Li Z, Kaneda Y, Ichikawa J (2003). Serotonin receptors: their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 27:1159-1172.
129. Mignon L, Wolf WA (2002). Postsynaptic 5-HT(1A) receptors mediate an increase in locomotor activity in the monoamine-depleted rat. Psychopharmacology (Berl) 163:85-94.
130. Miyamoto S, Duncan GE, Marx CE, Lieberman JA (2005). Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry 10:79-104.
131. Nagai T, Murai R, Matsui K, Kamei H, Noda Y, Furukawa H, Nabeshima T (2009). Aripiprazole ameliorates phencyclidine-induced impairment of recognition memory through dopamine D1 and serotonin 5-HT1A receptors. Psychopharmacology (Berl) 202:315-328.
132. Nagatsu T, Sawada M (2009). L-DOPA therapy for Parkinson's disease: past, present, and future. Parkinsonism Relat Disord 15 Suppl 1:S3-S8.
133. Navailles S, De Deurwaerdère P (2011). Presynaptic control of serotonin on striatal dopamine function. Psychopharmacology (Berl) 213:213-242.
134. Neal-Beliveau BS, Joyce JN, Lucki I (1993). Serotonergic involvement in haloperidol-induced catalepsy. J Pharmacol Exp Ther 265:207-217.
135. Nedergaard S, Bolam JP, Greenfield SA (1988). Facilitation of a dendritic calcium conductance by 5-hydroxytryptamine in the substantia nigra. Nature 333:174-177.
136. Newman-Tancredi A (2010). The importance of 5-HT1A receptor agonism in antipsychotic drug action: rationale and perspectives. Curr Opin Investig Drugs 11:802-812.
137. Newman-Tancredi A, Kleven MS (2011). Comparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor properties. Psychopharmacology (Berl) 216:451-473.
138. Newman-Tancredi A, Chaput C, Verriele L, Millan MJ (1996). Clozapine is a partial agonist at cloned, human serotonin 5-HT1A receptors. Neuropharmacology 35:119-121.
139. Ohno Y, Shimizu S, Imaki J, Ishihara S, Sofue N, Sasa M, Kawai Y (2008). Anticataleptic 8-OH-DPAT preferentially counteracts with haloperidol-induced Fos expression in the dorsolateral striatum and the core region of the nucleus accumbens. Neuropharmacology 55:717-723.
140. Ohno Y, Shimizu S, Imaki J (2009). Effects of tandospirone, a 5-HT1A agonistic anxiolytic agent, on haloperidol-induced catalepsy and forebrain Fos expression in mice. J Pharmacol Sci 109:593-599.
141. Ohno Y, Shimizu S, Tokudome K (2013). Pathophysiological roles of serotonergic system in regulating extrapyramidal motor functions. Biol Pharm Bull 36:1396-1400.
142. Olpe HR, Koella WP (1977). The response of striatal cells upon stimulation of the dorsal and median raphe nuclei. Brain Res 122:357-360.
143. Palkovits M, Brownstein M, Saavedra JM (1974). Serotonin content of the brain stem nuclei in the rat. Brain Res 80:237-249.
144. Parent A, Descarries L, Beaudet A (1981). Organization of ascending serotonin systems in the adult rat brain. A radioautographic study after intraventricular administration of [3H]5-hydroxytryptamine. Neuroscience 6:115-138.
145. Pazos A, Palacios JM (1985). Quantitative autoradiographic mapping of serotonin receptors in the rat brain. I. Serotonin-1 receptors. Brain Res 346:205-230.
146. Pickar D, Su TP, Weinberger DR, Coppola R, Malhotra AK, Knable MB, et al. (1996). Individual variation in D2 dopamine receptor occupancy in clozapinetreated patients. Am J Psychiatry 153:1571-1578.
147. Pompeiano M, Palacios JM, Mengod G (1992). Distribution and cellular localization of mRNA coding for 5-HT1A receptor in the rat brain: correlation with receptor binding. J Neurosci 12:440-453.
148. Pontone G, WilliamsJR, Bassett SS, Marsh L (2006). Clinical features associated with impulse control disorders in Parkinson disease. Neurology 67:1258-1261.
149. Prinssen EP, Kleven MS, Koek W (1999). Interactions between neuroleptics and 5-HT(1A) ligands in preclinical behavioral models for antipsychotic and extrapyramidal effects. Psychopharmacology (Berl) 144:20-29.
150. Prinssen EP, Colpaert FC, Koek W (2002). 5-HT1A receptor activation and anticataleptic effects: high-efficacy agonists maximally inhibit haloperidol-induced catalepsy. Eur J Pharmacol 453:217-221.
151. Rasmusson AM, Goldstein LE, Deutch AY, Bunney BS, Roth RH (1994). 5-HT1a agonist + /-8-OH-DPAT modulates basal and stress-induced changes in medial prefrontal cortical dopamine. Synapse 18:218-224.
152. Rezak M (2007). Current pharmacotherapeutic treatment options in Parkinson's disease. Dis Mon 53:214-222.
153. Ribaric S (2012). The pharmacological properties and therapeutic use of apomorphine. Molecules 17:5289-5309.
154. Richard IH, Schiffer RB, Kurlan R (1996). Anxiety and Parkinson's disease. J Neuropsychiatry Clin Neurosci 8:383-392.
155. Robertson HA, Peterson MR, Murphy K, Robertson GS (1989). D1-dopamine receptor agonists selectively activate striatal c-fos independent of rotational behaviour. Brain Res 503:346-349.
156. Rollema H, Lu Y, Schmidt AW, Sprouse JS, Zorn SH (2000). 5-HT(1A) receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex. Biol Psychiatry 48:229-237.
157. Rössler W, Salize HJ, van Os J, Riecher-Rössler A (2005). Size of burden of schizophrenia and psychotic disorders. Eur Neuropsychopharmacol 15:399-409.
158. Rupp A, Keith SJ (1993). The costs of schizophrenia. Assessing the burden. Psychiatr Clin North Am 16:413-423.
159. Saavedra JM (1977). Distribution of serotonin and synthesizing enzymes in discrete areas of the brain. Fed Proc 36:2134-2141.
160. Samii A, Nutt JG, Ransom BR (2004). Parkinson's disease. Lancet 363:1783-1793.
161. Santana N, Bortolozzi A, Serrats J, Mengod G, Artigas F (2004). Expression of serotonin1A and serotonin2A receptors in pyramidal and GABAergic neurons of the rat prefrontal cortex. Cereb Cortex 14:1100-1109.
162. Sargent PA, Kjaer KH, Bench CJ, Rabiner EA, Messa C, Meyer J, et al. (2000). Brain serotonin1A receptor binding measured by positron emission tomography with [11C]WAY-100635: effects of depression and antidepressant treatment. Arch Gen Psychiatry 57:174-180.
163. Scatton B, Javoy-Agid F, Rouquier L, Dubois B, Agid Y (1983). Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease. Brain Res 275:321-328.
164. Schreiber R, Newman-Tancredi A (2014). Improving cognition in schizophrenia with antipsychotics that elicit neurogenesis through 5-HT(1A) receptor activation. Neurobiol Learn Mem 110:72-80.
165. Seeman P (2002). Atypical antipsychotics: mechanism of action. Can J Psychiatry 47:27-38.
166. Selvaraj S, Arnone D, Cappai A, Howes O (2014). Alterations in the serotonin system in schizophrenia: a systematic review and meta-analysis of postmortem and molecular imaging studies. Neurosci Biobehav Rev 45:233-245.
167. Shapiro DA, Renock S, Arrington E, Chiodo LA, Liu LX, Sibley DR, et al. (2003). Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 28:1400-1411.
168. Sharp T, Bramwell SR, Hjorth S, Grahame-Smith DG (1989). Pharmacological characterization of 8-OH-DPAT-induced inhibition of rat hippocampal 5-HT release in vivo as measured by microdialysis. Br J Pharmacol 98:989-997.
169. Shimizu S, Ohno Y (2013). Improving the treatment of Parkinson's disease: a novel approach by modulating 5-HT1A receptors. Aging Dis 4:1-13.
170. Shimizu S, Tatara A, Imaki J, Ohno Y (2010). Role of cortical and striatal 5-HT1A receptors in alleviating antipsychotic-induced extrapyramidal disorders. Prog Neuropsychopharmacol Biol Psychiatry 34:877-881.
171. Shimizu S, Mizuguchi Y, Ohno Y (2013). Improving the treatment of schizophrenia: role of 5-HT receptors in modulating cognitive and extrapyramidal motor functions. CNS Neurol Disord Drug Targets 12:861-869.
172. Shireen E, Haleem DJ (2005). Motor effects of buspirone: relationship with dopamine and serotonin in the striatum. J Coll Physicians Surg Pak 15:753-756.
173. Smith Y, Bevan MD, Shink E, Bolam JP (1998). Microcircuitry of the direct and indirect pathways of the basal ganglia. Neuroscience 86:353-387.
174. Steinbusch HW, Nieuwenhuys R (1981). Localization of serotonin-like immunoreactivity in the central nervous system and pituitary of the rat, with special references to the innervation of the hypothalamus. Adv Exp Med Biol 133:7-35.
175. Struhal W, Guger M, Hödl S, Ung SC, Bach M, Ransmayr G (2012). Attempted suicide under high dose dopaminergic therapy including apomorphine. Wien Klin Wochenschr 124:461-463.
176. Sumiyoshi T, Higuchi Y, Uehara T (2013). Neural basis for the ability of atypical antipsychotic drugs to improve cognition in schizophrenia. Front Behav Neurosci 7:140.
177. Tamminga CA (2002). Partial dopamine agonists in the treatment of psychosis. J Neural Transm 109:411-420.
178. Tanda G, Carboni E, Frau R, Di Chiara G (1994). Increase of extracellular dopamine in the prefrontal cortex: a trait of drugs with antidepressant potential? Psychopharmacology (Berl) 115:285-288.
179. Tauscher J, Kapur S, Verhoeff NP, Hussey DF, Daskalakis ZJ, Tauscher-Wisniewski S, et al. (2002). Brain serotonin 5-HT(1A) receptor binding in schizophrenia measured by positron emission tomography and [11C] WAY-100635. Arch Gen Psychiatry 59:514-520.
180. Timmerman W, Abercrombie ED (1996). Amphetamine-induced release of dendritic dopamine in substantia nigra pars reticulata: D1-mediated behavioral and electrophysiological effects. Synapse 23:280-291.
181. Tomiyama M, Kimura T, Maeda T, Kannari K, Matsunaga M, Baba M (2005). A serotonin 5-HT1A receptor agonist prevents behavioral sensitization to L-DOPA in a rodent model of Parkinson's disease. Neurosci Res 52:185-194.
182. Toth M (2003). 5-HT1A receptor knockout mouse as a genetic model of anxiety. Eur J Pharmacol 463:177-184.
183. Turner RS, Desmurget M (2010). Basal ganglia contributions to motor control: a vigorous tutor. Curr Opin Neurobiol 20:704-716.
184. Ungerstedt U (1976). 6-hydroxydopamine-induced degeneration of the nigrostriatal dopamine pathway: the turning syndrome. Pharmacol Ther B 2:37-40.
185. Vertes RP (1991). A PHA-L analysis of ascending projections of the dorsal raphe nucleus in the rat. J Comp Neurol 313:643-668.
186. Voon V, Hassan K, Zurowski M, de Souza M, Thomsen T, Fox S, et al. (2006). Prevalence of repetitive and reward-seeking behaviors in Parkinson disease. Neurology 67:1254-1257.
187. Wadenberg ML, Young KA, Richter JT, Hicks PB (1999). Effects of local application of 5-hydroxytryptamine into the dorsal or median raphe nuclei on haloperidol-induced catalepsy in the rat. Neuropharmacology 38:151-156.
188. Werkman TR, Glennon JC, Wadman WJ, McCreary AC (2006). Dopamine receptor pharmacology: interactions with serotonin receptors and significance for the aetiology and treatment of schizophrenia. CNS Neurol Disord Drug Targets 5:3-23.
189. Wilson WH (1996). Time required for initial improvement during clozapine treatment of refractory schizophrenia. Am J Psychiatry 153:951-952.
190. Wong EH, Tarazi FI, Shahid M (2010). The effectiveness of multi-target agents in schizophrenia and mood disorders: relevance of receptor signature to clinical action. Pharmacol Ther 126:173-185.
191. Worrel JA, Marken PA, Beckman SE, Ruehter VL (2000). Atypical antipsychotic agents: a critical review. Am J Health Syst Pharm 57:238-255.
192. Yakel JL, Trussell LO, Jackson MB (1988). Three serotonin responses in cultured mouse hippocampal and striatal neurons. J Neurosci 8:1273-1285.
193. Yamamoto M, Schapira AH (2008). Dopamine agonists in Parkinson's disease. Expert Rev Neurother 8:671-677.
194. Yasuno F, Suhara T, Nakayama T, Ichimiya T, Okubo Y, Takano A, et al. (2003). Inhibitory effect of hippocampal 5-HT1A receptors on human explicit memory. Am J Psychiatry 160:334-340.
195. Yasuno F, Suhara T, Ichimiya T, Takano A, Ando T, Okubo Y (2004). Decreased 5-HT1A receptor binding in amygdala of schizophrenia. Biol Psychiatry 55:439-444.
196. Zold CL, Escande MV, Pomata PE, Riquelme LA, Murer MG (2012). Striatal NMDA receptors gate cortico-pallidal synchronization in a rat model of Parkinson's disease. Neurobiol Dis 47:38-48.